We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Humans May Benefit from Canine Bladder Cancer Assay

By LabMedica International staff writers
Posted on 23 Jun 2014
A unique group of proteins have been identified that indicate the presence of transitional cell carcinoma, the most common cause of bladder cancer and may lead to a new assay which could better diagnose this disease in both dogs and humans. More...


An improved assay to detect this serious disease much earlier in both animals and humans should be possible, and may even become affordable enough that it could be used as an over-the-counter product to test urine.

Scientists at Oregon State University (Corvallis, OR, USA) analyzed the canine urinary proteome as a noninvasive diagnostic tool for transitional cell carcinoma (TCC) identification. Urine was collected from 12 dogs in three cohorts (healthy, urinary tract infection, TCC) and analyzed using liquid chromatography tandem mass spectrometry (LC–MS/MS).

Peptide sample were analyzed using a linear ion trap combined with a Fourier transform ion cyclotron resonance (LTQ-FT) mass spectrometer (Thermo Scientific; Waltham, MA, USA) coupled to a nanoAcquity Ultra Performance Liquid Chromatography (UPLC) system (Waters, Milford, MA, USA). The scientists also performed immunoblots on a cellular fractions and polymerase chain reaction for detection of bacterial infections.

The team used the science of proteomics to identify 96 proteins that appear related to transitional cell carcinoma. This is a fairly common cancer in dogs, often as a result of exposure to pesticides, herbicides, and poor quality foods; and in humans is closely related to smoking. The presence of four proteins, macrophage capping protein, peroxiredoxin 5, heterogeneous nuclear ribonucleoproteins A2/B, and apolipoprotein A1, was confirmed via immunoblotting. The groups of proteins identified in the study were 90% accurate in diagnosing cancer, and investigators say they hope to improve upon that with continued studies.

The authors concluded that their novel approach to biomarker discovery can be applied to studies in humans to determine whether the same biomarkers can predict TCC in humans and dogs, and if not, which biomarkers are unique to urine from human TCC patients. The study was published in the June 2014 issue of the journal Analytical Biochemistry.

Related Links:

Oregon State University 
Thermo Scientific
Waters



Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Staining Management Software
DakoLink
New
Chlamydia Trachomatis Test
Aptima Chlamydia Trachomatis Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: CellLENS enables the potential precision therapy strategies against specific immune cell populations in the tissue environment (Photo courtesy of MIT)

New AI System Uncovers Hidden Cell Subtypes to Advance Cancer Immunotherapy

To produce effective targeted therapies for cancer, scientists need to isolate the genetic and phenotypic characteristics of cancer cells, both within and across different tumors. These differences significantly... Read more

Pathology

view channel
Image: Micrograph showing the distribution of misfolded proteins in myeloma cells (Photo courtesy of Helmholtz Munich)

Novel Method Tracks Cancer Treatment in Cells Without Dyes or Labels

Multiple myeloma is a blood cancer that affects plasma cells in the bone marrow, leading to abnormal protein production, weakened immunity, and organ damage. Traditional methods for evaluating myeloma... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.